-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson plans to buy eye disease biotech company Ollin Biosciences for up to $3.4 billion. Under the agreement, Johnson & Johnson may pay Ollin supporters $2.2 billion in upfront cash, as well as another $1.2 billion in potential milestone payments.

Zhitongcaijing·11/16/2026 00:09:05
Listen to the news
Johnson & Johnson plans to buy eye disease biotech company Ollin Biosciences for up to $3.4 billion. Under the agreement, Johnson & Johnson may pay Ollin supporters $2.2 billion in upfront cash, as well as another $1.2 billion in potential milestone payments.